Gemtuzumab Ozogamicin (anti-CD33 ADC for AML) and Inotuzumab Ozogamicin (anti-CD22 ADC for ALL): Gentuzumab Ozogamicin carry a calicheamicin payload. Here, CD33 is linked to acute myeloid leukemia.